| Year |
Citation |
Score |
| 2023 |
Ngo K, Lopez Mateos D, Han Y, Rouen KC, Ahn SH, Wulff H, Clancy CE, Yarov-Yarovoy V, Vorobyov I. Elucidating molecular mechanisms of protoxin-II state-specific binding to the human NaV1.7 channel. The Journal of General Physiology. 156. PMID 38127314 DOI: 10.1085/jgp.202313368 |
0.312 |
|
| 2023 |
Alexander SPH, Mathie AA, Peters JA, Veale EL, Striessnig J, Kelly E, Armstrong JF, Faccenda E, Harding SD, Davies JA, Aldrich RW, Attali B, Baggetta AM, Becirovic E, Biel M, ... ... Wulff H, et al. The Concise Guide to PHARMACOLOGY 2023/24: Ion channels. British Journal of Pharmacology. S145-S222. PMID 38123150 DOI: 10.1111/bph.16178 |
0.532 |
|
| 2023 |
Emigh Cortez AM, DeMarco KR, Furutani K, Bekker S, Sack JT, Wulff H, Clancy CE, Vorobyov I, Yarov-Yarovoy V. Structural modeling of hERG channel-drug interactions using Rosetta. Frontiers in Pharmacology. 14: 1244166. PMID 38035013 DOI: 10.3389/fphar.2023.1244166 |
0.385 |
|
| 2023 |
Saxena S, Nuyens V, Rodts C, Jamar K, Albert A, Seidel L, Cherkaoui-Malki M, Boogaerts JG, Wulff H, Maze M, Kruys V, Vamecq J. Involvement of KCa3.1 channel activity in immediate perioperative cognitive and neuroinflammatory outcomes. Bmc Anesthesiology. 23: 80. PMID 36927341 DOI: 10.1186/s12871-023-02030-2 |
0.401 |
|
| 2023 |
Ngo K, Mateos DL, Rouen K, Han Y, Wulff H, Clancy CE, Yarov-Yarovoy V, Vorobyov I. Elucidating Molecular Mechanisms of Protoxin-2 State-specific Binding to the Human Na 1.7 Channel. Biorxiv : the Preprint Server For Biology. PMID 36909474 DOI: 10.1101/2023.02.27.530360 |
0.315 |
|
| 2022 |
Kuzmenkov AI, Peigneur S, Nasburg JA, Mineev KS, Nikolaev MV, Pinheiro-Junior EL, Arseniev AS, Wulff H, Tytgat J, Vassilevski AA. Apamin structure and pharmacology revisited. Frontiers in Pharmacology. 13: 977440. PMID 36188602 DOI: 10.3389/fphar.2022.977440 |
0.368 |
|
| 2022 |
Rivera A, Nasburg JA, Shim H, Shmukler BE, Kitten J, Wohlgemuth JG, Dlott JS, Snyder LM, Brugnara C, Wulff H, Alper SL. The erythroid K-Cl cotransport inhibitor [(Dihydroindenyl)oxy]acetic acid (DIOA) blocks erythroid Ca-activated K channel KCNN4. American Journal of Physiology. Cell Physiology. PMID 35848620 DOI: 10.1152/ajpcell.00240.2022 |
0.325 |
|
| 2022 |
Srinivasan SR, Huang H, Chang WC, Nasburg JA, Nguyen HM, Strassmaier T, Wulff H, Shakkottai VG. Discovery of novel activators of large-conductance calcium-activated potassium channels for the treatment of cerebellar ataxia. Molecular Pharmacology. PMID 35489717 DOI: 10.1124/molpharm.121.000478 |
0.448 |
|
| 2022 |
Orfali R, Nam YW, Nguyen HM, Rahman MA, Yang G, Cui M, Wulff H, Zhang M. Channelopathy-causing mutations in the SA/SB and HA/HB helices of K2.3 and K3.1 channels alter their apparent Ca sensitivity. Cell Calcium. 102: 102538. PMID 35030515 DOI: 10.1016/j.ceca.2022.102538 |
0.338 |
|
| 2021 |
Chen YJ, Cui Y, Singh L, Wulff H. The potassium channel Kv1.3 as a therapeutic target for immunocytoprotection after reperfusion. Annals of Clinical and Translational Neurology. PMID 34617690 DOI: 10.1002/acn3.51456 |
0.335 |
|
| 2021 |
Alexander SP, Mathie A, Peters JA, Veale EL, Striessnig J, Kelly E, Armstrong JF, Faccenda E, Harding SD, Pawson AJ, Southan C, Davies JA, Aldrich RW, Attali B, Baggetta AM, ... ... Wulff H, et al. THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Ion channels. British Journal of Pharmacology. 178: S157-S245. PMID 34529831 DOI: 10.1111/bph.15539 |
0.533 |
|
| 2021 |
Ramesha S, Rayaprolu S, Bowen CA, Giver CR, Bitarafan S, Nguyen HM, Gao T, Chen MJ, Nwabueze N, Dammer EB, Engstrom AK, Xiao H, Pennati A, Seyfried NT, Katz DJ, ... ... Wulff H, et al. Unique molecular characteristics and microglial origin of Kv1.3 channel-positive brain myeloid cells in Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 33649184 DOI: 10.1073/pnas.2013545118 |
0.327 |
|
| 2021 |
Fomina AF, Nguyen HM, Wulff H. Kv1.3 inhibition attenuates neuroinflammation through disruption of microglial calcium signaling. Channels (Austin, Tex.). 15: 67-78. PMID 33356832 DOI: 10.1080/19336950.2020.1853943 |
0.381 |
|
| 2020 |
Ong ST, Bajaj S, Tanner MR, Chang SC, Krishnarjuna B, Ng XR, Morales RAV, Chen MW, Luo D, Patel D, Yasmin S, Ng JJH, Zhuang Z, Nguyen HM, El Sahili A, ... ... Wulff H, et al. Modulation of Lymphocyte Potassium Channel K1.3 by Membrane-Penetrating, Joint-Targeting Immunomodulatory Plant Defensin. Acs Pharmacology & Translational Science. 3: 720-736. PMID 32832873 DOI: 10.1021/acsptsci.0c00035 |
0.336 |
|
| 2020 |
Lai LK, Valdearcos M, Morioka K, Saxena S, Feng X, Li R, Uchida Y, Lijun A, Li W, Pan J, Koliwad S, Marcucio R, Wulff H, Maze M. Blocking Kv1.3 potassium channels psrevents postoperative neuroinflammation and cognitive decline without impairing wound healing in mice. British Journal of Anaesthesia. PMID 32624183 DOI: 10.1016/J.Bja.2020.05.018 |
0.438 |
|
| 2020 |
Sarkar S, Nguyen HM, Malovic E, Luo J, Langley M, Palanisamy BN, Singh N, Manne S, Neal M, Gabrielle M, Abdalla A, Anantharam P, Rokad D, Panicker N, Singh V, ... ... Wulff H, et al. Kv1.3 modulates neuroinflammation and neurodegeneration in Parkinson's disease. The Journal of Clinical Investigation. PMID 32597830 DOI: 10.1172/Jci136174 |
0.38 |
|
| 2020 |
Nguyen HM, di Lucente J, Chen YJ, Cui Y, Ibrahim RH, Pennington MW, Jin LW, Maezawa I, Wulff H. Biophysical basis for Kv1.3 regulation of membrane potential changes induced by P2X4-mediated calcium entry in microglia. Glia. PMID 32525239 DOI: 10.1002/Glia.23847 |
0.498 |
|
| 2020 |
Lozano-Gerona J, Oliván-Viguera A, Delgado-Wicke P, Singh V, Brown BM, Tapia-Casellas E, Pueyo E, Valero MS, Garcia-Otín ÁL, Giraldo P, Abarca-Lachen E, Surra JC, Osada J, Hamilton KL, Raychaudhuri SP, ... ... Wulff H, et al. Conditional KCa3.1-transgene induction in murine skin produces pruritic eczematous dermatitis with severe epidermal hyperplasia and hyperkeratosis. Plos One. 15: e0222619. PMID 32150577 DOI: 10.1371/Journal.Pone.0222619 |
0.369 |
|
| 2019 |
Mathew John C, Khaddaj Mallat R, Mishra RC, George G, Singh V, Turnbull JD, Umeshappa CS, Kendrick DJ, Kim T, Fauzi FM, Visser F, Fedak PW, Wulff H, Braun AP. SKA-31, an activator of Ca-activated K channels, improves cardiovascular function in aging. Pharmacological Research. 104539. PMID 31707036 DOI: 10.1016/J.Phrs.2019.104539 |
0.461 |
|
| 2019 |
Shim H, Brown BM, Singh L, Singh V, Fettinger JC, Yarov-Yarovoy V, Wulff H. The Trials and Tribulations of Structure Assisted Design of K Channel Activators. Frontiers in Pharmacology. 10: 972. PMID 31616290 DOI: 10.3389/Fphar.2019.00972 |
0.423 |
|
| 2019 |
Brown BM, Shim H, Christophersen P, Wulff H. Pharmacology of Small- and Intermediate-Conductance Calcium-Activated Potassium Channels. Annual Review of Pharmacology and Toxicology. PMID 31337271 DOI: 10.1146/Annurev-Pharmtox-010919-023420 |
0.494 |
|
| 2019 |
Jin LW, Lucente JD, Nguyen HM, Singh V, Singh L, Chavez M, Bushong T, Wulff H, Maezawa I. Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease. Annals of Clinical and Translational Neurology. 6: 723-738. PMID 31019997 DOI: 10.1002/Acn3.754 |
0.381 |
|
| 2019 |
D'Alessandro G, Monaco L, Catacuzzeno L, Antonangeli F, Santoro A, Esposito V, Franciolini F, Wulff H, Limatola C. Radiation Increases Functional KCa3.1 Expression and Invasiveness in Glioblastoma. Cancers. 11. PMID 30813636 DOI: 10.3390/Cancers11030279 |
0.319 |
|
| 2019 |
Brown BM, Nguyen HM, Wulff H. Recent advances in our understanding of the structure and function of more unusual cation channels. F1000research. 8. PMID 30755796 DOI: 10.12688/F1000Research.17163.1 |
0.504 |
|
| 2019 |
Wulff H, Christophersen P, Colussi P, Chandy KG, Yarov-Yarovoy V. Antibodies and venom peptides: new modalities for ion channels. Nature Reviews. Drug Discovery. PMID 30728472 DOI: 10.1038/S41573-019-0013-8 |
0.501 |
|
| 2019 |
Aldrich R, Chandy KG, Grissmer S, Gutman GA, Kaczmarek LK, Wei AD, Wulff H. Calcium- and sodium-activated potassium channels (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database Iuphar/Bps Guide to Pharmacology Cite. 2019. DOI: 10.2218/gtopdb/f69/2019.4 |
0.635 |
|
| 2019 |
Theng Ong S, Thomas G, Kannan S, Her Z, Rui Ng X, Chew X, Nguyen HM, Wulff H, Verma C, Chen Q, Ahmed M, Chandy KG. Novel Inhibitors of the Calcium-Activated K+ Channel KCa3.1 to Treat Non-Alcoholic Fatty Liver Disease and Liver Fibrosis Biophysical Journal. 116: 249a. DOI: 10.1016/J.Bpj.2018.11.1362 |
0.366 |
|
| 2019 |
Theng Ong S, Seng Ng A, Rui Ng X, Kua L, Lee FY, Tan S, Shim H, Prasannan P, DasGupta R, Tan IB, Wulff H, Chandy KG, Verma NK. Activation of Potassium Channel as a New Strategy to Boost Antitumour Immune Response Biophysical Journal. 116: 249a. DOI: 10.1016/J.Bpj.2018.11.1361 |
0.437 |
|
| 2018 |
Di Lucente J, Nguyen HM, Wulff H, Jin LW, Maezawa I. The voltage-gated potassium channel Kv1.3 is required for microglial pro-inflammatory activation in vivo. Glia. PMID 30043400 DOI: 10.1002/Glia.23457 |
0.455 |
|
| 2018 |
Cocozza G, di Castro MA, Carbonari L, Grimaldi A, Antonangeli F, Garofalo S, Porzia A, Madonna M, Mainiero F, Santoni A, Grassi F, Wulff H, D'Alessandro G, Limatola C. Ca-activated K channels modulate microglia affecting motor neuron survivalin hSOD1 mice. Brain, Behavior, and Immunity. PMID 29981425 DOI: 10.1016/J.Bbi.2018.07.002 |
0.403 |
|
| 2018 |
Slavi N, Toychiev AH, Kosmidis S, Ackert J, Bloomfield SA, Wulff H, Viswanathan S, Lampe PD, Srinivas M. Suppression of connexin 43 phosphorylation promotes astrocyte survival and vascular regeneration in proliferative retinopathy. Proceedings of the National Academy of Sciences of the United States of America. PMID 29891713 DOI: 10.1073/Pnas.1803907115 |
0.316 |
|
| 2018 |
Grimaldi A, D'Alessandro G, Di Castro MA, Lauro C, Singh V, Pagani F, Sforna L, Grassi F, Di Angelantonio S, Catacuzzeno L, Wulff H, Limatola C, Catalano M. Kv1.3 activity perturbs the homeostatic properties of astrocytes in glioma. Scientific Reports. 8: 7654. PMID 29769580 DOI: 10.1038/S41598-018-25940-5 |
0.443 |
|
| 2018 |
Mishra RC, Rahman MM, Davis MJ, Wulff H, Hill MA, Braun AP. Alpha -adrenergic stimulation selectively enhances endothelium-mediated vasodilation in rat cremaster arteries. Physiological Reports. 6: e13703. PMID 29756401 DOI: 10.14814/Phy2.13703 |
0.344 |
|
| 2018 |
Bushart DD, Chopra R, Singh V, Murphy GG, Wulff H, Shakkottai VG. Targeting potassium channels to treat cerebellar ataxia. Annals of Clinical and Translational Neurology. 5: 297-314. PMID 29560375 DOI: 10.1002/Acn3.527 |
0.402 |
|
| 2018 |
Bednenko J, Harriman R, Mariën L, Nguyen HM, Agrawal A, Papoyan A, Bisharyan Y, Cardarelli J, Cassidy-Hanley D, Clark T, Pedersen D, Abdiche Y, Harriman W, van der Woning B, de Haard H, ... ... Wulff H, et al. A multiplatform strategy for the discovery of conventional monoclonal antibodies that inhibit the voltage-gated potassium channel Kv1.3. Mabs. 0. PMID 29494279 DOI: 10.1080/19420862.2018.1445451 |
0.465 |
|
| 2018 |
Chen YJ, Nguyen HM, Maezawa I, Jin LW, Wulff H. Inhibition of the potassium channel Kv1.3 reduces infarction and inflammation in ischemic stroke. Annals of Clinical and Translational Neurology. 5: 147-161. PMID 29468176 DOI: 10.1016/J.Bpj.2017.11.1133 |
0.404 |
|
| 2018 |
Vorobyov I, Brown BM, DeMarco KR, Noskov SY, Yarov-Yarovoy V, Wulff H, Clancy CE. Molecular Determinants of Steroid Hormone and Drug Induced Arrhythmogenesis via hERG Channel Block Biophysical Journal. 114: 486a. DOI: 10.1016/J.Bpj.2017.11.2670 |
0.434 |
|
| 2018 |
Brown BM, Shim H, Wulff H. Mechanism of Gating of the Intermediate-Conductance Calcium-Activated Potassium Channel (KCa3.1) Biophysical Journal. 114: 308a-309a. DOI: 10.1016/J.Bpj.2017.11.1748 |
0.473 |
|
| 2018 |
Shim H, Wulff H, DeMarco K, Yarov-yarovoy V. Structural Modeling of Full-Length KCa Channels using Rosetta Biophysical Journal. 114: 307a. DOI: 10.1016/J.Bpj.2017.11.1743 |
0.452 |
|
| 2017 |
Maezawa I, Nguyen HM, Di Lucente J, Jenkins DP, Singh V, Hilt S, Kim K, Rangaraju S, Levey AI, Wulff H, Jin LW. Kv1.3 inhibition as a potential microglia-targeted therapy for Alzheimer's disease: preclinical proof of concept. Brain : a Journal of Neurology. PMID 29272333 DOI: 10.1093/Brain/Awx346 |
0.545 |
|
| 2017 |
Nam YW, Orfali R, Liu T, Yu K, Cui M, Wulff H, Zhang M. Structural insights into the potency of SK channel positive modulators. Scientific Reports. 7: 17178. PMID 29214998 DOI: 10.1038/S41598-017-16607-8 |
0.492 |
|
| 2017 |
Pillozzi S, D'Amico M, Bartoli G, Gasparoli L, Petroni G, Crociani O, Marzo T, Guerriero A, Messori L, Severi M, Udisti R, Wulff H, Chandy KG, Becchetti A, Arcangeli A. The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells. British Journal of Cancer. PMID 29161243 DOI: 10.1038/Bjc.2017.392 |
0.331 |
|
| 2017 |
Brown BM, Shim H, Wulff H. Are there Superagonists for Calcium-activated Potassium Channels? Channels (Austin, Tex.). 0. PMID 28876978 DOI: 10.1080/19336950.2017.1376971 |
0.459 |
|
| 2017 |
Brown BM, Shim H, Zhang M, Yarov-Yarovoy V, Wulff H. Structural Determinants for the Selectivity of the Positive KCa3.1 Gating Modulator 5-Methylnaphtho[2,1-d]oxazol-2-amine (SKA-121). Molecular Pharmacology. PMID 28760780 DOI: 10.1124/Mol.117.109421 |
0.4 |
|
| 2017 |
Brown BM, Pressley B, Wulff H. KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma. Current Neuropharmacology. PMID 28676010 DOI: 10.2174/1570159X15666170630164226 |
0.446 |
|
| 2017 |
Mousavi Nik A, Pressly B, Singh V, Antrobus S, Hulsizer S, Rogawski MA, Wulff H, Pessah IN. Rapid Throughput Analysis of GABAA Receptor Subtype Modulators and Blockers Using DiSBAC1(3) Membrane Potential Red Dye. Molecular Pharmacology. PMID 28428226 DOI: 10.1124/Mol.117.108563 |
0.372 |
|
| 2017 |
Barnych B, Vasylieva N, Joseph T, Hulsizer S, Nguyen H, Cajka T, Pessah I, Wulff H, Gee S, Hammock B. Development of tetramethylenedisulfotetramine (TETS) hapten library: synthesis, electrophysiological studies and immune response in rabbits. Chemistry (Weinheim An Der Bergstrasse, Germany). PMID 28411375 DOI: 10.1002/Chem.201700783 |
0.3 |
|
| 2017 |
Nguyen HM, Blomster LV, Christophersen P, Wulff H. Potassium channel expression and function in microglia: Plasticity and possible species variations. Channels (Austin, Tex.). 0. PMID 28277939 DOI: 10.1080/19336950.2017.1300738 |
0.463 |
|
| 2017 |
Kaczmarek LK, Aldrich RW, Chandy KG, Grissmer S, Wei AD, Wulff H. International Union of Basic and Clinical Pharmacology. C. Nomenclature and Properties of Calcium-Activated and Sodium-Activated Potassium Channels. Pharmacological Reviews. 69: 1-11. PMID 28267675 DOI: 10.1124/Pr.116.012864 |
0.648 |
|
| 2017 |
Nguyen HM, Singh V, Pressly B, Jenkins DP, Wulff H, Yarov-Yarovoy V. Structural Insights into the Atomistic Mechanisms of Action of Small Molecule Inhibitors Targeting the KCa3.1 Channel Pore. Molecular Pharmacology. PMID 28126850 DOI: 10.1124/Mol.116.108068 |
0.625 |
|
| 2017 |
Shim H, Brown B, Nguyen HM, Yarov-Yarovoy V, Wulff H. Rational Design of K Ca 2 Channel Activators Biophysical Journal. 112: 412a-413a. DOI: 10.1016/J.Bpj.2016.11.2567 |
0.45 |
|
| 2017 |
Nguyen HM, Grössinger EM, Horiuchi M, Davis KW, Jin L, Maezawa I, Wulff H. Differential K + Channels Expression in “Classically” and “Alternatively” Activated Microglia Biophysical Journal. 112: 333a-334a. DOI: 10.1016/J.Bpj.2016.11.1805 |
0.46 |
|
| 2016 |
Nguyen HM, Grössinger EM, Horiuchi M, Davis KW, Jin LW, Maezawa I, Wulff H. Differential Kv1.3, KCa3.1, and Kir2.1 expression in "classically" and "alternatively" activated microglia. Glia. PMID 27696527 DOI: 10.1002/Glia.23078 |
0.429 |
|
| 2016 |
Glaser N, Little C, Lo W, Cohen M, Tancredi D, Wulff H, O'Donnell M. Treatment with the KCa3.1 inhibitor TRAM-34 during diabetic ketoacidosis reduces inflammatory changes in the brain. Pediatric Diabetes. PMID 27174668 DOI: 10.1111/Pedi.12396 |
0.343 |
|
| 2016 |
D'Alessandro G, Grimaldi A, Chece G, Porzia A, Esposito V, Santoro A, Salvati M, Mainiero F, Ragozzino D, Di Angelantonio S, Wulff H, Catalano M, Limatola C. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. Oncotarget. PMID 27096953 DOI: 10.18632/Oncotarget.8761 |
0.366 |
|
| 2016 |
Oliván-Viguera A, Valero MS, Pinilla E, Amor S, García-Villalón ÁL, Coleman N, Laría C, Calvín-Tienza V, García-Otín ÁL, Fernández-Fernández JM, Murillo MD, Gálvez JA, Díaz-de-Villegas MD, Badorrey R, Simonsen U, ... ... Wulff H, et al. Vascular reactivity profile of novel KC a 3.1-selective positive-gating modulators in the coronary vascular bed. Basic & Clinical Pharmacology & Toxicology. PMID 26821335 DOI: 10.1111/Bcpt.12560 |
0.621 |
|
| 2016 |
Grimaldi A, D'Alessandro G, Golia MT, Grössinger EM, Di Angelantonio S, Ragozzino D, Santoro A, Esposito V, Wulff H, Catalano M, Limatola C. KCa3.1 inhibition switches the phenotype of glioma-infiltrating microglia/macrophages Cell Death and Disease. 7. DOI: 10.1038/Cddis.2016.73 |
0.357 |
|
| 2016 |
Brown BM, Shim H, Yarov-Yarovoy V, Wulff H. Structural Determinants for Selectivity of the Positive KCa Channel Gating Modulator, SKA-121 Biophysical Journal. 110: 114a. DOI: 10.1016/J.Bpj.2015.11.667 |
0.447 |
|
| 2016 |
Chen Y, Nguyen HM, Maezawa I, Jin L, Wulff H. The Voltage-Gated Potassium Channel Kv1.3 as a Target for Inhibiting Detrimental M1 Microglia Functions Biophysical Journal. 110: 527a-528a. DOI: 10.1016/J.Bpj.2015.11.2821 |
0.368 |
|
| 2016 |
Nguyen HM, Singh L, Wulff H, Yarov-Yarovoy V. Validation of KCa3.1 Channel Small Molecules Interaction Sites Predicted by Rosetta Biophysical Journal. 110: 447a. DOI: 10.1016/J.Bpj.2015.11.2405 |
0.486 |
|
| 2016 |
Köhler R, Oliván-Viguera A, Wulff H. Endothelial Small- and Intermediate-Conductance K Channels and Endothelium-Dependent Hyperpolarization as Drug Targets in Cardiovascular Disease Advances in Pharmacology. DOI: 10.1016/Bs.Apha.2016.04.002 |
0.508 |
|
| 2015 |
Chen YJ, Nguyen HM, Maezawa I, Grössinger EM, Garing AL, Köhler R, Jin LW, Wulff H. The potassium channel KCa3.1 constitutes a pharmacological target for neuroinflammation associated with ischemia/reperfusion stroke. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. PMID 26661208 DOI: 10.1177/0271678X15611434 |
0.384 |
|
| 2015 |
Wulff H, Christophersen P. Recent developments in ion channel pharmacology. Channels (Austin, Tex.). 9: 335. PMID 26646476 DOI: 10.1080/19336950.2015.1077650 |
0.444 |
|
| 2015 |
Hong L, Singh V, Wulff H, Tombola F. Interrogation of the intersubunit interface of the open Hv1 proton channel with a probe of allosteric coupling. Scientific Reports. 5: 14077. PMID 26365828 DOI: 10.1038/Srep14077 |
0.43 |
|
| 2015 |
Dell'Orco JM, Wasserman AH, Chopra R, Ingram MA, Hu YS, Singh V, Wulff H, Opal P, Orr HT, Shakkottai VG. Neuronal Atrophy Early in Degenerative Ataxia Is a Compensatory Mechanism to Regulate Membrane Excitability. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 11292-307. PMID 26269637 DOI: 10.1523/Jneurosci.1357-15.2015 |
0.369 |
|
| 2015 |
Mishra R, Mitchell JR, Gibbons-Kroeker C, Wulff H, Belenkie I, Tyberg JV, Braun AP. A Pharmacologic Activator of Endothelial KCa Channels Increases Systemic Conductance and Reduces Arterial Pressure in an Anesthetized Pig Model. Vascular Pharmacology. PMID 26239885 DOI: 10.1016/J.Vph.2015.07.016 |
0.302 |
|
| 2015 |
Christophersen P, Wulff H. Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1). Channels (Austin, Tex.). 9: 336-43. PMID 26217968 DOI: 10.1080/19336950.2015.1071748 |
0.505 |
|
| 2015 |
Feske S, Wulff H, Skolnik EY. Ion channels in innate and adaptive immunity. Annual Review of Immunology. 33: 291-353. PMID 25861976 DOI: 10.1146/Annurev-Immunol-032414-112212 |
0.42 |
|
| 2015 |
Roach KM, Feghali-Bostwick C, Wulff H, Amrani Y, Bradding P. Human lung myofibroblast TGFβ1-dependent Smad2/3 signalling is Ca(2+)-dependent and regulated by KCa3.1 K(+) channels. Fibrogenesis & Tissue Repair. 8: 5. PMID 25829947 DOI: 10.1186/S13069-015-0022-0 |
0.359 |
|
| 2015 |
Mishra RC, Wulff H, Hill MA, Braun AP. Inhibition of Myogenic Tone in Rat Cremaster and Cerebral Arteries by SKA-31, an Activator of Endothelial KCa2.3 and KCa3.1 Channels. Journal of Cardiovascular Pharmacology. 66: 118-27. PMID 25815673 DOI: 10.1097/Fjc.0000000000000252 |
0.46 |
|
| 2015 |
Cao Z, Zou X, Cui Y, Hulsizer S, Lein PJ, Wulff H, Pessah IN. Rapid throughput analysis demonstrates that chemicals with distinct seizurogenic mechanisms differentially alter Ca2+ dynamics in networks formed by hippocampal neurons in culture. Molecular Pharmacology. 87: 595-605. PMID 25583085 DOI: 10.1124/Mol.114.096701 |
0.356 |
|
| 2015 |
Chen YJ, Wallace BK, Yuen N, Jenkins DP, Wulff H, O'Donnell ME. Blood-brain barrier KCa3.1 channels: evidence for a role in brain Na uptake and edema in ischemic stroke. Stroke; a Journal of Cerebral Circulation. 46: 237-44. PMID 25477223 DOI: 10.1161/Strokeaha.114.007445 |
0.563 |
|
| 2015 |
Oliván-Viguera A, Valero MS, Coleman N, Brown BM, LarÃa C, Murillo MD, Gálvez JA, DÃaz-de-Villegas MD, Wulff H, Badorrey R, Köhler R. A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo. Molecular Pharmacology. 87: 338-48. PMID 25468883 DOI: 10.1124/Mol.114.095745 |
0.651 |
|
| 2015 |
Coleman N, Nguyen HM, Cao Z, Brown BM, Jenkins DP, Zolkowska D, Chen YJ, Tanaka BS, Goldin AL, Rogawski MA, Pessah IN, Wulff H. The riluzole derivative 2-amino-6-trifluoromethylthio-benzothiazole (SKA-19), a mixed KCa2 activator and NaV blocker, is a potent novel anticonvulsant. Neurotherapeutics : the Journal of the American Society For Experimental Neurotherapeutics. 12: 234-49. PMID 25256961 DOI: 10.1007/S13311-014-0305-Y |
0.738 |
|
| 2015 |
Waeckel L, Bertin F, Clavreul N, Damery T, Köhler R, Paysant J, Sansilvestri-Morel P, Simonet S, Vayssettes-Courchay C, Wulff H, Verbeuren TJ, Félétou M. Preserved regulation of renal perfusion pressure by small and intermediate conductance KCa channels in hypertensive mice with or without renal failure. PflüGers Archiv : European Journal of Physiology. 467: 817-31. PMID 24903240 DOI: 10.1007/S00424-014-1542-Y |
0.349 |
|
| 2015 |
Wulff H, Yarov-Yarovoy V. Small Molecule Modulation of Voltage-Gated Ion Channels Biophysical Journal. 108: 177a. DOI: 10.1016/J.Bpj.2014.11.977 |
0.522 |
|
| 2015 |
Grossinger EM, Nguyen HM, Chen Y, Maezawa I, Wulff H. M1 and M2 Microglia Exhibit Significant Differences in their K+ Channel Expression Biophysical Journal. 108: 586a. DOI: 10.1016/J.Bpj.2014.11.3195 |
0.398 |
|
| 2015 |
Nguyen HM, Wulff H, Yarov-Yarovoy V. Validation of KCa3.1 Channel Nifedipine Interaction Site Predicted by Rosetta Modeling Method Biophysical Journal. 108: 582a-583a. DOI: 10.1016/J.Bpj.2014.11.3181 |
0.531 |
|
| 2015 |
Hong L, Singh V, Wulff H, Tombola F. Allosteric Coupling between Open Subunits in the Hv1 Proton Channel Probed by Guanidino-Thiazoles Biophysical Journal. 108: 425a. DOI: 10.1016/J.Bpj.2014.11.2324 |
0.47 |
|
| 2015 |
Brown BM, Coleman N, Yarov-Yarovoy V, Wulff H. Positive KCa Channel Gating Modulators with Selectivity for KCa3.1 Biophysical Journal. 108: 20a. DOI: 10.1016/J.Bpj.2014.11.134 |
0.702 |
|
| 2014 |
Roach KM, Wulff H, Feghali-Bostwick C, Amrani Y, Bradding P. Increased constitutive αSMA and Smad2/3 expression in idiopathic pulmonary fibrosis myofibroblasts is KCa3.1-dependent. Respiratory Research. 15: 155. PMID 25476248 DOI: 10.1186/S12931-014-0155-5 |
0.421 |
|
| 2014 |
Kundu-Raychaudhuri S, Chen YJ, Wulff H, Raychaudhuri SP. Kv1.3 in psoriatic disease: PAP-1, a small molecule inhibitor of Kv1.3 is effective in the SCID mouse psoriasis--xenograft model. Journal of Autoimmunity. 55: 63-72. PMID 25175978 DOI: 10.1016/J.Jaut.2014.07.003 |
0.349 |
|
| 2014 |
Coleman N, Brown BM, Oliván-Viguera A, Singh V, Olmstead MM, Valero MS, Köhler R, Wulff H. New positive Ca2+-activated K+ channel gating modulators with selectivity for KCa3.1. Molecular Pharmacology. 86: 342-57. PMID 24958817 DOI: 10.1124/Mol.114.093286 |
0.688 |
|
| 2014 |
Chhabra S, Chang SC, Nguyen HM, Huq R, Tanner MR, Londono LM, Estrada R, Dhawan V, Chauhan S, Upadhyay SK, Gindin M, Hotez PJ, Valenzuela JG, Mohanty B, Swarbrick JD, ... Wulff H, et al. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 28: 3952-64. PMID 24891519 DOI: 10.1096/Fj.14-251967 |
0.389 |
|
| 2014 |
Koch Hansen L, Sevelsted-Møller L, Rabjerg M, Larsen D, Hansen TP, Klinge L, Wulff H, Knudsen T, Kjeldsen J, Köhler R. Expression of T-cell KV1.3 potassium channel correlates with pro-inflammatory cytokines and disease activity in ulcerative colitis. Journal of Crohn's & Colitis. 8: 1378-91. PMID 24793818 DOI: 10.1016/J.Crohns.2014.04.003 |
0.401 |
|
| 2014 |
Mishra RC, Wulff H, Cole WC, Braun AP. A pharmacologic activator of endothelial KCa channels enhances coronary flow in the hearts of type 2 diabetic rats. Journal of Molecular and Cellular Cardiology. 72: 364-73. PMID 24787473 DOI: 10.1016/J.Yjmcc.2014.04.013 |
0.317 |
|
| 2014 |
Luna-Cancalon K, Sikora KM, Pappas SS, Singh V, Wulff H, Paulson HL, Burmeister M, Shakkottai VG. Alterations in cerebellar physiology are associated with a stiff-legged gait in Atcay(ji-hes) mice. Neurobiology of Disease. 67: 140-8. PMID 24727095 DOI: 10.1016/J.Nbd.2014.03.020 |
0.337 |
|
| 2014 |
Cao Z, Cui Y, Nguyen HM, Jenkins DP, Wulff H, Pessah IN. Nanomolar bifenthrin alters synchronous Ca2+ oscillations and cortical neuron development independent of sodium channel activity. Molecular Pharmacology. 85: 630-9. PMID 24482397 DOI: 10.1124/Mol.113.090076 |
0.593 |
|
| 2014 |
Roach KM, Duffy SM, Coward W, Feghali-Bostwick C, Wulff H, Bradding P. Correction: The K+Channel KCa3.1 as a Novel Target for Idiopathic Pulmonary Fibrosis Plos One. 9. DOI: 10.1371/Annotation/790E86F8-3506-49D6-B7D0-7Dbbc580D808 |
0.395 |
|
| 2014 |
Coleman NT, Brown BM, Viguera AO, Köhler R, Wulff H. SKA-111, a Positive KCa Channel Gating Modulator with Selectivity for KCa3.1 Biophysical Journal. 106: 642a. DOI: 10.1016/J.Bpj.2013.11.3556 |
0.527 |
|
| 2014 |
Groessinger E, Weiss L, Chen M, Wulff H, Greil R, Kerschbaum H. Malignant Lymphoblasts in T Cell Acute Lymphoblastic Leukemia Express High Levels of Kv1.3 Biophysical Journal. 106: 551a. DOI: 10.1016/J.Bpj.2013.11.3069 |
0.474 |
|
| 2014 |
Yarov-Yarovoy V, Wulff H. Structural Modeling of KCa3.1 Channel Interaction with Small Molecules Biophysical Journal. 106: 542a. DOI: 10.1016/J.Bpj.2013.11.3022 |
0.535 |
|
| 2014 |
Wulff H, Chen Y, Jenkins PD, Nguyen H, Garing AL, Köhler R. The Microglial K+ Channels Kv1.3 and KCa3.1 as Potential Therapeutic Targets for Ischemic Stroke Biophysical Journal. 106: 433a. DOI: 10.1016/J.Bpj.2013.11.2437 |
0.425 |
|
| 2013 |
Roach KM, Roach KM, Duffy SM, Coward W, Feghali-Bostwick C, Wulff H, Bradding P. The K+ channel KCa3.1 as a novel target for idiopathic pulmonary fibrosis. Plos One. 8: e85244. PMID 24392001 DOI: 10.1371/Journal.Pone.0085244 |
0.413 |
|
| 2013 |
Jenkins DP, Yu W, Brown BM, Løjkner LD, Wulff H. Development of a QPatch automated electrophysiology assay for identifying KCa3.1 inhibitors and activators. Assay and Drug Development Technologies. 11: 551-60. PMID 24351043 DOI: 10.1089/Adt.2013.543 |
0.629 |
|
| 2013 |
Chen YJ, Lam J, Gregory CR, Schrepfer S, Wulff H. The Ca²âº-activated K⺠channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy. Plos One. 8: e81006. PMID 24312257 DOI: 10.1371/Journal.Pone.0081006 |
0.441 |
|
| 2013 |
Koshy S, Wu D, Hu X, Tajhya RB, Huq R, Khan FS, Pennington MW, Wulff H, Yotnda P, Beeton C. Blocking KCa3.1 channels increases tumor cell killing by a subpopulation of human natural killer lymphocytes. Plos One. 8: e76740. PMID 24146918 DOI: 10.1371/Journal.Pone.0076740 |
0.352 |
|
| 2013 |
D'Alessandro G, Catalano M, Sciaccaluga M, Chece G, Cipriani R, Rosito M, Grimaldi A, Lauro C, Cantore G, Santoro A, Fioretti B, Franciolini F, Wulff H, Limatola C. KCa3.1 channels are involved in the infiltrative behavior of glioblastoma in vivo. Cell Death & Disease. 4: e773. PMID 23949222 DOI: 10.1038/Cddis.2013.279 |
0.443 |
|
| 2013 |
Lam J, Coleman N, Garing AL, Wulff H. The therapeutic potential of small-conductance KCa2 channels in neurodegenerative and psychiatric diseases. Expert Opinion On Therapeutic Targets. 17: 1203-20. PMID 23883298 DOI: 10.1517/14728222.2013.823161 |
0.675 |
|
| 2013 |
Wulff H, Yarov-Yarovoy V. Channels: Sticking to nooks and crannies. Nature Chemical Biology. 9: 473-4. PMID 23868316 DOI: 10.1038/Nchembio.1292 |
0.466 |
|
| 2013 |
Van Der Velden J, Sum G, Barker D, Koumoundouros E, Barcham G, Wulff H, Castle N, Bradding P, Snibson K. K(Ca)3.1 channel-blockade attenuates airway pathophysiology in a sheep model of chronic asthma. Plos One. 8: e66886. PMID 23826167 DOI: 10.1371/Journal.Pone.0066886 |
0.377 |
|
| 2013 |
Radtke J, Schmidt K, Wulff H, Köhler R, de Wit C. Activation of KCa3.1 by SKA-31 induces arteriolar dilatation and lowers blood pressure in normo- and hypertensive connexin40-deficient mice. British Journal of Pharmacology. 170: 293-303. PMID 23734697 DOI: 10.1111/Bph.12267 |
0.397 |
|
| 2013 |
Bi D, Toyama K, Lemaître V, Takai J, Fan F, Jenkins DP, Wulff H, Gutterman DD, Park F, Miura H. The intermediate conductance calcium-activated potassium channel KCa3.1 regulates vascular smooth muscle cell proliferation via controlling calcium-dependent signaling. The Journal of Biological Chemistry. 288: 15843-53. PMID 23609438 DOI: 10.1074/Jbc.M112.427187 |
0.577 |
|
| 2013 |
Bradding P, Wulff H. Ion channels. Thorax. 68: 974-7. PMID 23564342 DOI: 10.1136/thoraxjnl-2012-202786 |
0.363 |
|
| 2013 |
Oliván-Viguera A, Valero MS, Murillo MD, Wulff H, García-Otín AL, Arbonés-Mainar JM, Köhler R. Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3. Plos One. 8: e58614. PMID 23516517 DOI: 10.1371/Journal.Pone.0058614 |
0.518 |
|
| 2013 |
Hua X, Deuse T, Chen YJ, Wulff H, Stubbendorff M, Köhler R, Miura H, Länger F, Reichenspurner H, Robbins RC, Schrepfer S. The potassium channel KCa3.1 as new therapeutic target for the prevention of obliterative airway disease. Transplantation. 95: 285-92. PMID 23325003 DOI: 10.1097/Tp.0B013E318275A2F4 |
0.495 |
|
| 2013 |
Girodet PO, Ozier A, Carvalho G, Ilina O, Ousova O, Gadeau AP, Begueret H, Wulff H, Marthan R, Bradding P, Berger P. Ca(2+)-activated K(+) channel-3.1 blocker TRAM-34 attenuates airway remodeling and eosinophilia in a murine asthma model. American Journal of Respiratory Cell and Molecular Biology. 48: 212-9. PMID 23204391 DOI: 10.1165/Rcmb.2012-0103Oc |
0.35 |
|
| 2013 |
Mishra RC, Belke D, Wulff H, Braun AP. SKA-31, a novel activator of SK(Ca) and IK(Ca) channels, increases coronary flow in male and female rat hearts. Cardiovascular Research. 97: 339-48. PMID 23118129 DOI: 10.1093/Cvr/Cvs326 |
0.403 |
|
| 2013 |
Wulff H, Köhler R. Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets. Journal of Cardiovascular Pharmacology. 61: 102-12. PMID 23107876 DOI: 10.1097/Fjc.0B013E318279Ba20 |
0.502 |
|
| 2013 |
Strøbæk D, Brown DT, Jenkins DP, Chen YJ, Coleman N, Ando Y, Chiu P, Jørgensen S, Demnitz J, Wulff H, Christophersen P. NS6180, a new K(Ca) 3.1 channel inhibitor prevents T-cell activation and inflammation in a rat model of inflammatory bowel disease. British Journal of Pharmacology. 168: 432-44. PMID 22891655 DOI: 10.1111/J.1476-5381.2012.02143.X |
0.661 |
|
| 2013 |
Hua X, Deuse T, Chen Y, Wulff H, Koehler R, Stubbendorff M, Reichenspurner H, Robbins R, Schrepfer S. The calcium-activated potassium channel KCa3.1 is critically involved in T cell activation The Thoracic and Cardiovascular Surgeon. 61. DOI: 10.1055/S-0032-1332449 |
0.465 |
|
| 2012 |
Nguyen W, Howard BL, Jenkins DP, Wulff H, Thompson PE, Manallack DT. Structure-activity relationship exploration of Kv1.3 blockers based on diphenoxylate. Bioorganic & Medicinal Chemistry Letters. 22: 7106-9. PMID 23084278 DOI: 10.1016/J.Bmcl.2012.09.080 |
0.569 |
|
| 2012 |
Lambertsen KL, Gramsbergen JB, Sivasaravanaparan M, Ditzel N, Sevelsted-Møller LM, Oliván-Viguera A, Rabjerg M, Wulff H, Köhler R. Genetic KCa3.1-deficiency produces locomotor hyperactivity and alterations in cerebral monoamine levels. Plos One. 7: e47744. PMID 23077667 DOI: 10.1371/Journal.Pone.0047744 |
0.373 |
|
| 2012 |
Bodendiek SB, Rubinos C, Trelles MP, Coleman N, Jenkins DP, Wulff H, Srinivas M. Triarylmethanes, a new class of cx50 inhibitors. Frontiers in Pharmacology. 3: 106. PMID 22685432 DOI: 10.3389/Fphar.2012.00106 |
0.764 |
|
| 2012 |
Maezawa I, Jenkins DP, Jin BE, Wulff H. Microglial KCa3.1 Channels as a Potential Therapeutic Target for Alzheimer's Disease. International Journal of Alzheimer's Disease. 2012: 868972. PMID 22675649 DOI: 10.1155/2012/868972 |
0.56 |
|
| 2012 |
Vandendriessche T, Kopljar I, Jenkins DP, Diego-Garcia E, Abdel-Mottaleb Y, Vermassen E, Clynen E, Schoofs L, Wulff H, Snyders D, Tytgat J. Purification, molecular cloning and functional characterization of HelaTx1 (Heterometrus laoticus): the first member of a new κ-KTX subfamily. Biochemical Pharmacology. 83: 1307-17. PMID 22305749 DOI: 10.1016/J.Bcp.2012.01.021 |
0.586 |
|
| 2012 |
Chi V, Pennington MW, Norton RS, Tarcha EJ, Londono LM, Sims-Fahey B, Upadhyay SK, Lakey JT, Iadonato S, Wulff H, Beeton C, Chandy KG. Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune diseases. Toxicon : Official Journal of the International Society On Toxinology. 59: 529-46. PMID 21867724 DOI: 10.1016/J.Toxicon.2011.07.016 |
0.477 |
|
| 2012 |
Damkjaer M, Nielsen G, Bodendiek S, Staehr M, Gramsbergen JB, de Wit C, Jensen BL, Simonsen U, Bie P, Wulff H, Köhler R. Pharmacological activation of KCa3.1/KCa2.3 channels produces endothelial hyperpolarization and lowers blood pressure in conscious dogs. British Journal of Pharmacology. 165: 223-34. PMID 21699504 DOI: 10.1111/J.1476-5381.2011.01546.X |
0.425 |
|
| 2012 |
Hua X, Deuse T, Chen Y, Wulff H, Koehler R, Reichenspurner H, Robbins R, Schrepfer S. The intermediate-conductance potassium channel as a potential new target for the prevention of airway allograft rejection The Thoracic and Cardiovascular Surgeon. 60. DOI: 10.1055/S-0031-1297427 |
0.459 |
|
| 2012 |
Maezawa I, Jenkins PD, Sexton J, Wulff H, Jin L. P2-112: The role of potassium channel Kv1.3 in Aß-induced microglia activation Alzheimer's & Dementia. 8: P301-P301. DOI: 10.1016/J.Jalz.2012.05.817 |
0.489 |
|
| 2012 |
Strøbæk D, Brown DT, David Jenkins P, Chiu P, Jørgensen S, Demnitz J, Wulff H, Christophersen P. NS6180, a New KCa3.1 Blocker, Inhibits T-Cell Activation and Dampens Inflammation in a Rat Model of Inflammatory Bowel Disease Biophysical Journal. 102: 688a-689a. DOI: 10.1016/J.Bpj.2011.11.3741 |
0.492 |
|
| 2012 |
Jenkins DP, Maezawa I, Wulff H, Jin L. Microglial Kv1.3 Channels as a Potential Target for Alzheimer's Disease Biophysical Journal. 102: 679a. DOI: 10.1016/J.Bpj.2011.11.3691 |
0.366 |
|
| 2011 |
Lam J, Wulff H. The Lymphocyte Potassium Channels Kv1.3 and KCa3.1 as Targets for Immunosuppression. Drug Development Research. 72: 573-584. PMID 22241939 DOI: 10.1002/Ddr.20467 |
0.423 |
|
| 2011 |
Shakkottai VG, do Carmo Costa M, Dell'Orco JM, Sankaranarayanan A, Wulff H, Paulson HL. Early changes in cerebellar physiology accompany motor dysfunction in the polyglutamine disease spinocerebellar ataxia type 3. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 31: 13002-14. PMID 21900579 DOI: 10.1523/Jneurosci.2789-11.2011 |
0.439 |
|
| 2011 |
Chen YJ, Raman G, Bodendiek S, O'Donnell ME, Wulff H. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia/reperfusion stroke. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 31: 2363-74. PMID 21750563 DOI: 10.1038/Jcbfm.2011.101 |
0.31 |
|
| 2011 |
Jenkins DP, Strøbæk D, Hougaard C, Jensen ML, Hummel R, Sørensen US, Christophersen P, Wulff H. Negative gating modulation by (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphthylamine (NS8593) depends on residues in the inner pore vestibule: pharmacological evidence of deep-pore gating of K(Ca)2 channels. Molecular Pharmacology. 79: 899-909. PMID 21363929 DOI: 10.1124/Mol.110.069807 |
0.585 |
|
| 2011 |
Hasenau AL, Nielsen G, Morisseau C, Hammock BD, Wulff H, Köhler R. Improvement of endothelium-dependent vasodilations by SKA-31 and SKA-20, activators of small- and intermediate-conductance Ca 2+-activated K +-channels Acta Physiologica. 203: 117-126. PMID 21362152 DOI: 10.1111/J.1748-1716.2010.02240.X |
0.458 |
|
| 2011 |
Hao B, Chen ZW, Zhou XJ, Zimin PI, Miljanich GP, Wulff H, Wang YX. Identification of phase-I metabolites and chronic toxicity study of the Kv1.3 blocker PAP-1 (5-(4-phenoxybutoxy)psoralen) in the rat. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 41: 198-211. PMID 21070145 DOI: 10.3109/00498254.2010.532886 |
0.747 |
|
| 2011 |
Maezawa I, Zimin PI, Wulff H, Jin LW. Amyloid-beta protein oligomer at low nanomolar concentrations activates microglia and induces microglial neurotoxicity. The Journal of Biological Chemistry. 286: 3693-706. PMID 20971854 DOI: 10.1074/Jbc.M110.135244 |
0.763 |
|
| 2011 |
Hua X, Deuse T, Chen Y, Wulff H, Köhler R, Reichenspurner H, Robbins R, Schrepfer S. 563 Identifying the Potassium Channel KCa3.1 as New Therapeutic Target To Prevent Airway Allograft Rejection The Journal of Heart and Lung Transplantation. 30: S189. DOI: 10.1016/J.Healun.2011.01.575 |
0.302 |
|
| 2010 |
Wulff H, Castle NA. Therapeutic potential of KCa3.1 blockers: recent advances and promising trends. Expert Review of Clinical Pharmacology. 3: 385-96. PMID 22111618 DOI: 10.1586/Ecp.10.11 |
0.4 |
|
| 2010 |
Wulff H. Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840. Expert Opinion On Therapeutic Patents. 20: 1759-65. PMID 20954790 DOI: 10.1517/13543776.2010.528392 |
0.452 |
|
| 2010 |
Nguyen W, Howard BL, Neale DS, Thompson PE, White PJ, Wulff H, Manallack DT. Use of kv1.3 blockers for inflammatory skin conditions Current Medicinal Chemistry. 17: 2882-2896. PMID 20858170 DOI: 10.2174/092986710792065072 |
0.45 |
|
| 2010 |
Zimin PI, Garic B, Bodendiek SB, Mahieux C, Wulff H, Zhorov BS. Potassium channel block by a tripartite complex of two cationophilic ligands and a potassium ion. Molecular Pharmacology. 78: 588-99. PMID 20601455 DOI: 10.1124/Mol.110.064014 |
0.819 |
|
| 2010 |
Di L, Srivastava S, Zhdanova O, Ding Y, Li Z, Wulff H, Lafaille M, Skolnik EY. Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis. Proceedings of the National Academy of Sciences of the United States of America. 107: 1541-6. PMID 20080610 DOI: 10.1073/Pnas.0910133107 |
0.436 |
|
| 2010 |
Köhler R, Kaistha BP, Wulff H. Vascular KCa-channels as therapeutic targets in hypertension and restenosis disease. Expert Opinion On Therapeutic Targets. 14: 143-55. PMID 20055714 DOI: 10.1517/14728220903540257 |
0.45 |
|
| 2010 |
Shepherd MC, Sabir SR, McSharry C, Wulff H, Bradding P. S139 The K+ channel KCa3.1 is a novel target for the treatment of idiopathic pulmonary fibrosis Thorax. 65: A63-A63. DOI: 10.1136/thx.2010.150946.40 |
0.303 |
|
| 2010 |
Meyberg D, Deuse T, Wulff H, Köhler R, Reichenspurner H, Schrepfer S. Identifying the potassium channel KCa3.1 as new therapeutic target to prevent chronic airway allograft rejection The Thoracic and Cardiovascular Surgeon. 58. DOI: 10.1055/S-0029-1247062 |
0.44 |
|
| 2010 |
Meyberg D, Deuse T, Wulff H, Kohler R, Reichenspurner H, Schrepfer S. 196: Identifying the Potassium Channel KCa3.1 as a New Therapeutic Target To Prevent Chronic Airway Allograft Rejection The Journal of Heart and Lung Transplantation. 29: S69-S69. DOI: 10.1016/J.Healun.2009.11.206 |
0.44 |
|
| 2010 |
Jenkins DP, Hougaard C, Jensen ML, Hummel R, Sørensen U, Wulff H, Christophersen P, Strøbæk D. NS8593-Mediated Negative Gating Modulation Depends on Residues in the Inner Pore Vestibule of Kca2 Channels Biophysical Journal. 98: 125a. DOI: 10.1016/J.Bpj.2009.12.678 |
0.483 |
|
| 2010 |
Wulff H, Chen Y, Schrepfer S, Köhler R. Kca3.1 Blockers as Potential New Drugs for the Prevention of Renal Fibrosis and Chronic Allograft Rejection Biophysical Journal. 98: 124a. DOI: 10.1016/J.Bpj.2009.12.676 |
0.376 |
|
| 2010 |
Zimin PI, Garic B, Wulff H, Zhorov BS. Potassium Channel Block by a Tripartite Complex of Neutral Ligands with a Potassium Ion Biophysical Journal. 98: 115a. DOI: 10.1016/J.Bpj.2009.12.629 |
0.818 |
|
| 2010 |
Bodendiek SB, Rubinos C, Srinivas M, Wulff H. New Classes of Gap Junction Channel Blockers for Cx43 and Cx50 Biophysical Journal. 98: 94a. DOI: 10.1016/J.Bpj.2009.12.531 |
0.483 |
|
| 2010 |
Wulff H, Rauer H, Duering T, Hanselmann C, Ruff K, Wrisch A, Grissmer S, Haensel W. ChemInform Abstract: Alkoxypsoralens, Novel Nonpeptide Blockers of Shaker-Type K+ Channels: Synthesis and Photoreactivity. Cheminform. 30: no-no. DOI: 10.1002/chin.199912147 |
0.355 |
|
| 2009 |
Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nature Reviews. Drug Discovery. 8: 982-1001. PMID 19949402 DOI: 10.1038/Nrd2983 |
0.455 |
|
| 2009 |
Grgic I, Kiss E, Kaistha BP, Busch C, Kloss M, Sautter J, Müller A, Kaistha A, Schmidt C, Raman G, Wulff H, Strutz F, Gröne HJ, Köhler R, Hoyer J. Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proceedings of the National Academy of Sciences of the United States of America. 106: 14518-23. PMID 19706538 DOI: 10.1073/Pnas.0903458106 |
0.341 |
|
| 2009 |
Bradding P, Wulff H. The K+ channels K(Ca)3.1 and K(v)1.3 as novel targets for asthma therapy. British Journal of Pharmacology. 157: 1330-9. PMID 19681865 DOI: 10.1111/J.1476-5381.2009.00362.X |
0.466 |
|
| 2009 |
Srivastava S, Di L, Zhdanova O, Li Z, Vardhana S, Wan Q, Yan Y, Varma R, Backer J, Wulff H, Dustin ML, Skolnik EY. The class II phosphatidylinositol 3 kinase C2beta is required for the activation of the K+ channel KCa3.1 and CD4 T-cells. Molecular Biology of the Cell. 20: 3783-91. PMID 19587117 DOI: 10.1091/Mbc.E09-05-0390 |
0.444 |
|
| 2009 |
Brähler S, Kaistha A, Schmidt VJ, Wölfle SE, Busch C, Kaistha BP, Kacik M, Hasenau AL, Grgic I, Si H, Bond CT, Adelman JP, Wulff H, de Wit C, Hoyer J, et al. Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation. 119: 2323-32. PMID 19380617 DOI: 10.1161/Circulationaha.108.846634 |
0.438 |
|
| 2009 |
Bodendiek SB, Mahieux C, Hänsel W, Wulff H. 4-Phenoxybutoxy-substituted heterocycles--a structure-activity relationship study of blockers of the lymphocyte potassium channel Kv1.3. European Journal of Medicinal Chemistry. 44: 1838-52. PMID 19056148 DOI: 10.1016/J.Ejmech.2008.10.033 |
0.448 |
|
| 2009 |
Sankaranarayanan A, Raman G, Busch C, Schultz T, Zimin PI, Hoyer J, Köhler R, Wulff H. Naphtho[1,2-d]thiazol-2-ylamine (SKA-31), a new activator of KCa2 and KCa3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Molecular Pharmacology. 75: 281-95. PMID 18955585 DOI: 10.1124/Mol.108.051425 |
0.816 |
|
| 2009 |
Zimin PI, Garic B, Wulff H, Zhorov BS. Mapping the Binding Site of the Alkoxypsoralen PAP-1 in the Voltage-Gated K+ Channel Kv1.3 Biophysical Journal. 96: 176a. DOI: 10.1016/J.Bpj.2008.12.818 |
0.807 |
|
| 2009 |
Lal R, Puglisi JL, Wulff H, Bers DM. Ca++T LAB - A Computational Model for Intracellular Calcium Signaling In T Lymphocytes Biophysical Journal. 96: 122a. DOI: 10.1016/J.Bpj.2008.12.541 |
0.429 |
|
| 2009 |
Wulff H, Sankaranarayanan A, Raman G, Busch C, Schultz T, Zimin PI, Hoyer J, Köhler R. SKA-31, A New Activator of KCa2 And KCa3.1 Potassium Channels, Potentiates the EDHF Response and Lowers Blood Pressure Biophysical Journal. 96: 475a-476a. DOI: 10.1016/J.Bpj.2008.12.2461 |
0.817 |
|
| 2009 |
Strobaek D, Jensen ML, Hougaard C, Sørensen US, Brown DT, Jenkins DP, Wulff H, Christophersen P. Pharmacological Evidence For Deep Pore Gating In SK Channels Biophysical Journal. 96: 474a. DOI: 10.1016/J.Bpj.2008.12.2452 |
0.495 |
|
| 2009 |
Bodendiek SB, Trelles MP, Srinivas M, Wulff H. Triarylmethanes - a New Class of Connexin Blockers Biophysical Journal. 96: 286a. DOI: 10.1016/J.Bpj.2008.12.1417 |
0.471 |
|
| 2008 |
Srivastava S, Zhdanova O, Di L, Li Z, Albaqumi M, Wulff H, Skolnik EY. Protein histidine phosphatase 1 negatively regulates CD4 T cells by inhibiting the K+ channel KCa3.1. Proceedings of the National Academy of Sciences of the United States of America. 105: 14442-6. PMID 18796614 DOI: 10.1016/J.Bpj.2008.12.3680 |
0.467 |
|
| 2008 |
Toyama K, Wulff H, Chandy KG, Azam P, Raman G, Saito T, Fujiwara Y, Mattson DL, Das S, Melvin JE, Pratt PF, Hatoum OA, Gutterman DD, Harder DR, Miura H. The intermediate-conductance calcium-activated potassium channel KCa3.1 contributes to atherogenesis in mice and humans. The Journal of Clinical Investigation. 118: 3025-37. PMID 18688283 DOI: 10.1172/Jci30836 |
0.425 |
|
| 2008 |
Wulff H. New light on the "old" chloride channel blocker DIDS. Acs Chemical Biology. 3: 399-401. PMID 18642798 DOI: 10.1021/Cb800140M |
0.48 |
|
| 2008 |
Albaqumi M, Srivastava S, Li Z, Zhdnova O, Wulff H, Itani O, Wallace DP, Skolnik EY. KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney International. 74: 740-9. PMID 18547995 DOI: 10.1038/Ki.2008.246 |
0.466 |
|
| 2008 |
Wulff H, Zhorov BS. K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chemical Reviews. 108: 1744-73. PMID 18476673 DOI: 10.1021/Cr078234P |
0.418 |
|
| 2008 |
Tharp DL, Wamhoff BR, Wulff H, Raman G, Cheong A, Bowles DK. Local delivery of the K Ca3.1 blocker, TRAM-34, prevents acute angioplasty-induced coronary smooth muscle phenotypic modulation and limits stenosis Arteriosclerosis, Thrombosis, and Vascular Biology. 28: 1084-1089. PMID 18309114 DOI: 10.1161/Atvbaha.107.155796 |
0.328 |
|
| 2007 |
Pereira LE, Villinger F, Wulff H, Sankaranarayanan A, Raman G, Ansari AA. Pharmacokinetics, toxicity, and functional studies of the selective Kv1.3 channel blocker 5-(4-phenoxybutoxy)psoralen in rhesus macaques Experimental Biology and Medicine. 232: 1338-1354. PMID 17959847 DOI: 10.3181/0705-Rm-148 |
0.409 |
|
| 2007 |
Wulff H, Kolski-Andreaco A, Sankaranarayanan A, Sabatier JM, Shakkottai V. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications Current Medicinal Chemistry. 14: 1437-1457. PMID 17584055 DOI: 10.2174/092986707780831186 |
0.547 |
|
| 2007 |
Azam P, Sankaranarayanan A, Homerick D, Griffey S, Wulff H. Targeting effector memory T cells with the small molecule Kv1.3 blocker PAP-1 suppresses allergic contact dermatitis. The Journal of Investigative Dermatology. 127: 1419-29. PMID 17273162 DOI: 10.1038/Sj.Jid.5700717 |
0.364 |
|
| 2007 |
Moritoki Y, Lian ZX, Wulff H, Yang GX, Chuang YH, Lan RY, Ueno Y, Ansari AA, Coppel RL, Mackay IR, Gershwin ME. AMA production in primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. Hepatology (Baltimore, Md.). 45: 314-22. PMID 17256753 DOI: 10.1002/Hep.21522 |
0.403 |
|
| 2007 |
Wulff H, Chen Y, Raman G, Gregory C. TRAM-34, a Blocker of the Calcium-activated Potassium Channel KCa3.1, Prevents Acute Transplant Rejection Clinical Immunology. 123: S173. DOI: 10.1016/J.Clim.2007.03.133 |
0.407 |
|
| 2006 |
Beeton C, Wulff H, Standifer NE, Azam P, Mullen KM, Pennington MW, Kolski-Andreaco A, Wei E, Grino A, Counts DR, Wang PH, LeeHealey CJ, S Andrews B, Sankaranarayanan A, Homerick D, et al. Kv1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proceedings of the National Academy of Sciences of the United States of America. 103: 17414-9. PMID 17088564 DOI: 10.1073/Pnas.0605136103 |
0.77 |
|
| 2006 |
Harvey AJ, Baell JB, Toovey N, Homerick D, Wulff H. A new class of blockers of the voltage-gated potassium channel Kv1.3 via modification of the 4- or 7-position of khellinone. Journal of Medicinal Chemistry. 49: 1433-41. PMID 16480279 DOI: 10.1021/Jm050839V |
0.473 |
|
| 2006 |
Mouhat S, Teodorescu G, Homerick D, Visan V, Wulff H, Wu Y, Grissmer S, Darbon H, De Waard M, Sabatier JM. Pharmacological profiling of Orthochirus scrobiculosus toxin 1 analogs with a trimmed N-terminal domain. Molecular Pharmacology. 69: 354-62. PMID 16234482 DOI: 10.1124/Mol.105.017210 |
0.429 |
|
| 2005 |
Wei AD, Gutman GA, Aldrich R, Chandy KG, Grissmer S, Wulff H. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels Pharmacological Reviews. 57: 463-472. PMID 16382103 DOI: 10.1124/Pr.57.4.9 |
0.515 |
|
| 2005 |
Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hänsel W, Wulff H. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Molecular Pharmacology. 68: 1254-70. PMID 16099841 DOI: 10.1124/Mol.105.015669 |
0.545 |
|
| 2005 |
Rus H, Pardo CA, Hu L, Darrah E, Cudrici C, Niculescu T, Niculescu F, Mullen KM, Allie R, Guo L, Wulff H, Beeton C, Judge SI, Kerr DA, Knaus HG, et al. The voltage-gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proceedings of the National Academy of Sciences of the United States of America. 102: 11094-9. PMID 16043714 DOI: 10.1073/Pnas.0501770102 |
0.358 |
|
| 2005 |
Beeton C, Pennington MW, Wulff H, Singh S, Nugent D, Crossley G, Khaytin I, Calabresi PA, Chen CY, Gutman GA, Chandy KG. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases. Molecular Pharmacology. 67: 1369-81. PMID 15665253 DOI: 10.1124/Mol.104.008193 |
0.431 |
|
| 2005 |
Mouhat S, Visan V, Ananthakrishnan S, Wulff H, Andreotti N, Grissmer S, Darbon H, De Waard M, Sabatier JM. K+ channel types targeted by synthetic OSK1, a toxin from Orthochirus scrobiculosus scorpion venom. The Biochemical Journal. 385: 95-104. PMID 15588251 DOI: 10.1042/Bj20041379 |
0.455 |
|
| 2004 |
Norton RS, Pennington MW, Wulff H. Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases. Current Medicinal Chemistry. 11: 3041-52. PMID 15578998 DOI: 10.2174/0929867043363947 |
0.529 |
|
| 2004 |
Wulff H, Knaus HG, Pennington M, Chandy KG. K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. Journal of Immunology (Baltimore, Md. : 1950). 173: 776-86. PMID 15240664 DOI: 10.4049/Jimmunol.173.2.776 |
0.436 |
|
| 2004 |
Vennekamp J, Wulff H, Beeton C, Calabresi PA, Grissmer S, Hänsel W, Chandy KG. Kv1.3-blocking 5-phenylalkoxypsoralens: a new class of immunomodulators. Molecular Pharmacology. 65: 1364-74. PMID 15155830 DOI: 10.1124/Mol.65.6.1364 |
0.529 |
|
| 2004 |
Chandy KG, Wulff H, Beeton C, Pennington M, Gutman GA, Cahalan MD. K+ channels as targets for specific immunomodulation. Trends in Pharmacological Sciences. 25: 280-9. PMID 15120495 DOI: 10.1016/J.Tips.2004.03.010 |
0.544 |
|
| 2004 |
Baell JB, Gable RW, Harvey AJ, Toovey N, Herzog T, Hänsel W, Wulff H. Khellinone derivatives as blockers of the voltage-gated potassium channel Kv1.3: synthesis and immunosuppressive activity. Journal of Medicinal Chemistry. 47: 2326-36. PMID 15084131 DOI: 10.1021/Jm030523S |
0.504 |
|
| 2004 |
Mouhat S, Mosbah A, Visan V, Wulff H, Delepierre M, Darbon H, Grissmer S, De Waard M, Sabatier JM. The 'functional' dyad of scorpion toxin Pi1 is not itself a prerequisite for toxin binding to the voltage-gated Kv1.2 potassium channels. The Biochemical Journal. 377: 25-36. PMID 12962541 DOI: 10.1042/Bj20030115 |
0.461 |
|
| 2003 |
Gutman GA, Chandy KG, Adelman JP, Aiyar J, Bayliss DA, Clapham DE, Covarriubias M, Desir GV, Furuichi K, Ganetzky B, Garcia ML, Grissmer S, Jan LY, Karschin A, Kim D, ... ... Wulff H, et al. International Union of Pharmacology. XLI. Compendium of voltage-gated ion channels: potassium channels. Pharmacological Reviews. 55: 583-6. PMID 14657415 DOI: 10.1124/Pr.55.4.9 |
0.494 |
|
| 2003 |
Wulff H, Beeton C, Chandy KG. Potassium channels as therapeutic targets for autoimmune disorders. Current Opinion in Drug Discovery & Development. 6: 640-7. PMID 14579513 |
0.413 |
|
| 2003 |
Köhler R, Wulff H, Eichler I, Kneifel M, Neumann D, Knorr A, Grgic I, Kämpfe D, Si H, Wibawa J, Real R, Borner K, Brakemeier S, Orzechowski HD, Reusch HP, et al. Blockade of the intermediate-conductance calcium-activated potassium channel as a new therapeutic strategy for restenosis. Circulation. 108: 1119-25. PMID 12939222 DOI: 10.1161/01.Cir.0000086464.04719.Dd |
0.464 |
|
| 2003 |
Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS. The Journal of Clinical Investigation. 111: 1703-13. PMID 12782673 DOI: 10.1172/Jci16921 |
0.381 |
|
| 2003 |
Beeton C, Wulff H, Singh S, Botsko S, Crossley G, Gutman GA, Cahalan MD, Pennington M, Chandy KG. A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes. The Journal of Biological Chemistry. 278: 9928-37. PMID 12511563 DOI: 10.1074/Jbc.M212868200 |
0.492 |
|
| 2003 |
Wulff H, Calabresi PA, Allie R, Yun S, Pennington M, Beeton C, Chandy KG. Erratum: The voltage-gated Kv1.3 K+ channel in effector memory T cells as new target for MS (Journal of Clinical Investigation (2003) 111 (1703-1713)) Journal of Clinical Investigation. 112. DOI: 10.1172/Jci200316921E |
0.429 |
|
| 2002 |
Bardien-Kruger S, Wulff H, Arieff Z, Brink P, Chandy KG, Corfield V. Characterisation of the human voltage-gated potassium channel gene, KCNA7, a candidate gene for inherited cardiac disorders, and its exclusion as cause of progressive familial heart block I (PFHBI). European Journal of Human Genetics : Ejhg. 10: 36-43. PMID 11896454 DOI: 10.1038/Sj.Ejhg.5200739 |
0.361 |
|
| 2002 |
Ayabe T, Wulff H, Darmoul D, Cahalan MD, Chandy KG, Ouellette AJ. Modulation of mouse Paneth cell alpha-defensin secretion by mIKCa1, a Ca2+-activated, intermediate conductance potassium channel. The Journal of Biological Chemistry. 277: 3793-800. PMID 11724775 DOI: 10.1074/Jbc.M107507200 |
0.428 |
|
| 2001 |
Beeton C, Wulff H, Barbaria J, Clot-Faybesse O, Pennington M, Bernard D, Cahalan MD, Chandy KG, Béraud E. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America. 98: 13942-7. PMID 11717451 DOI: 10.1073/Pnas.241497298 |
0.519 |
|
| 2001 |
Shakkottai VG, Regaya I, Wulff H, Fajloun Z, Tomita H, Fathallah M, Cahalan MD, Gargus JJ, Sabatier JM, Chandy KG. Design and characterization of a highly selective peptide inhibitor of the small conductance calcium-activated K+ channel, SkCa2. The Journal of Biological Chemistry. 276: 43145-51. PMID 11527975 DOI: 10.1074/Jbc.M106981200 |
0.509 |
|
| 2001 |
Cahalan MD, Wulff H, Chandy KG. Molecular properties and physiological roles of ion channels in the immune system. Journal of Clinical Immunology. 21: 235-52. PMID 11506193 DOI: 10.1023/A:1010958907271 |
0.52 |
|
| 2001 |
Wulff H, Gutman GA, Cahalan MD, Chandy KG. Delineation of the clotrimazole/TRAM-34 binding site on the intermediate conductance calcium-activated potassium channel, IKCa1. The Journal of Biological Chemistry. 276: 32040-5. PMID 11425865 DOI: 10.1074/Jbc.M105231200 |
0.509 |
|
| 2001 |
Chandy KG, Cahalan M, Pennington M, Norton RS, Wulff H, Gutman GA. Potassium channels in T lymphocytes: toxins to therapeutic immunosuppressants. Toxicon : Official Journal of the International Society On Toxinology. 39: 1269-76. PMID 11384714 DOI: 10.1016/S0041-0101(01)00120-9 |
0.473 |
|
| 2001 |
Fanger CM, Rauer H, Neben AL, Miller MJ, Rauer H, Wulff H, Rosa JC, Ganellin CR, Chandy KG, Cahalan MD. Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels. The Journal of Biological Chemistry. 276: 12249-56. PMID 11278890 DOI: 10.1074/Jbc.M011342200 |
0.486 |
|
| 2000 |
Ghanshani S, Wulff H, Miller MJ, Rohm H, Neben A, Gutman GA, Cahalan MD, Chandy KG. Up-regulation of the IKCa1 potassium channel during T-cell activation. Molecular mechanism and functional consequences. The Journal of Biological Chemistry. 275: 37137-49. PMID 10961988 DOI: 10.1074/Jbc.M003941200 |
0.527 |
|
| 2000 |
Wulff H, Miller MJ, Hansel W, Grissmer S, Cahalan MD, Chandy KG. Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: a potential immunosuppressant. Proceedings of the National Academy of Sciences of the United States of America. 97: 8151-6. PMID 10884437 DOI: 10.1073/Pnas.97.14.8151 |
0.488 |
|
| 2000 |
Strauss U, Wissel K, Jung S, Wulff H, Hänsel W, Zhu J, Rolfs A, Mix E. K+ channel-blocking alkoxypsoralens inhibit the immune response of encephalitogenic T line cells and lymphocytes from Lewis rats challenged for experimental autoimmune encephalomyelitis Immunopharmacology. 48: 51-63. PMID 10822089 DOI: 10.1016/S0162-3109(00)00177-6 |
0.451 |
|
| 1998 |
Wulff H, Rauer H, Düring T, Hanselmann C, Ruff K, Wrisch A, Grissmer S, Hänsel W. Alkoxypsoralens, novel nonpeptide blockers of Shaker-type K+ channels: Synthesis and photoreactivity Journal of Medicinal Chemistry. 41: 4542-4549. PMID 9804693 DOI: 10.1021/Jm981032O |
0.464 |
|
| Show low-probability matches. |